Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th
October 23 2017 - 8:30AM
Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its
third quarter 2017 financial results will be released after market
close on Monday, November 6th, 2017. Starting at 4:30 p.m.
EDT, Coherus’ management will host a conference call to discuss the
financial results and provide a general business
update.
After releasing third quarter 2017 financial results, we will
post them on the Coherus BioSciences website at
http://investors.coherus.com.
Conference Call InformationWhen: November 6,
2017 at 4:30 p.m. ETDial-in: (844) 452-6826 (toll free) or (765)
507-2587 (International)Conference ID: 99333721Webcast:
http://investors.coherus.com
Please join the conference call at least 10 minutes early to
register. The webcast will be archived on the Coherus
website.
About Coherus BioSciences, Inc.Coherus is a
leading pure-play, global biosimilar company that develops and
commercializes high-quality therapeutics for major regulated
markets. Biosimilars are intended for use in place of existing,
branded biologics to treat a range of chronic and often
life-threatening diseases, with the potential to reduce costs and
expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production, sales & marketing and
clinical-regulatory development, Coherus is positioned as a leader
in the global biosimilar marketplace. Coherus is advancing three
late-stage clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar),
CHS-0214 (etanercept biosimilar), and CHS-3351 (ranibizumab
injection biosimilar) as well as developing a robust pipeline of
future products in four therapeutic areas, oncology, immunology
(anti-TNF), ophthalmology and multiple sclerosis. For additional
information, please visit www.coherus.com.
CONTACT:Patrick O’BrienSenior Vice President, Investor
RelationsCoherus BioSciences, Inc.pobrien@coherus.com+1 (650)
649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024